目的 探讨哮喘宁颗粒联合布地奈德福莫特罗粉吸入剂治疗支气管哮喘急性发作期的临床疗效。方法 选取2018年3月-2020年3月在许昌市中心医院就诊的支气管哮喘急性发作期患者106例为研究对象，将所有患者按照随机数字表法随机分为对照组和治疗组，每组各有53例。对照组雾化吸入布地奈德福莫特罗粉吸入剂，1吸/次，2次/d；治疗组在对照组治疗的基础上口服哮喘宁颗粒，10 g/次，3次/d。两组均连续治疗14 d。观察两组的临床疗效，比较两组的肺功能和炎症因子。结果 治疗后，治疗组和对照组的总有效率分别为94.34%、81.13%，差异有统计学意义（P<0.05）。治疗后，两组的用力肺活量（FVC）、最大呼气流量（PEF）、第一秒用力呼气容积/用力肺活量（FEV₁/FVC）明显高于治疗前，差异均有统计学意义（P<0.05）；治疗后治疗组的FVC、PEF、FEV₁/FVC高于对照组，差异均有统计学意义（P<0.05）。治疗后，两组的超敏C反应蛋白（hs-CRP）、白细胞介素-6（IL-6）、白细胞介素-17（IL-17）水平明显低于治疗前，白细胞介素-35（IL-35）水平明显高于治疗前，差异均有统计学意义（P<0.05）；治疗后治疗组的hs-CRP、IL-6、IL-17水平低于对照组，IL-35水平高于对照组，差异均有统计学意义（P<0.05）。结论 哮喘宁颗粒联合布地奈德福莫特罗粉吸入剂治疗支气管哮喘急性发作期具有较好的临床疗效，可改善肺功能，降低血清炎症因子水平。

Objective To investigate the clinical efficacy of Xiaochuanning Granules combined with Budesonide and Formoterol Fumarate Powder for inhalation in treatment of bronchial asthma. Methods Patients (106 cases) with bronchial asthma in Xuchang Central Hospital from March 2018 to March 2020 were randomly divided into control and treatment groups, and each group had 53 cases. Patients in the control group were atomization inhalation administered with Budesonide and Formoterol Fumarate Powder for inhalation, 1 inhalation/time, twice daily. Patients in the treatment group were po administered with Xiaochuanning Granules on the basis of the control group, 10 g/time, three times daily. Patients in two groups were treated for 14 d. After treatment, the clinical efficacies were evaluated, and lung function and inflammatory factors in two groups were compared. Results After treatment, the total effective rates of the treatment group and the control group were 94.34% and 81.13%, respectively, and the difference was statistically significant (P<0.05). After treatment, FVC, PEF, and FEV₁/FVC of two groups were significantly higher than those before treatment (P<0.05). After treatment, FVC, PEF, and FEV₁/FVC of the treatment group were higher than those of the control group, and the differences were statistically significant (P<0.05). After treatment, the levels of hs-CRP, IL-6, and IL-17 in two groups were significantly lower than those before treatment, but the levels of IL-35 were significantly higher than those before treatment (P<0.05). After treatment, the levels of hs-CRP, IL-6, and IL-17 in the treatment group were lower than those in the control group, but the levels of IL-35 were higher than those in the control group (P<0.05). Conclusion Xiaochuanning Granules combined with Budesonide and Formoterol Fumarate Powder for inhalation has clinical curative effect in treatment of bronchial asthma, can improve the lung function of patients, and reduce the level of serum inflammatory factors.

R974

河南省中医药科学研究专项课题（2018ZY2030）